title: Hepatic stellate cells require a stiff environment for myofibroblastic differentiation.
abstract: The myofibroblastic differentiation of hepatic stellate cells (HSC) is a critical event in liver fibrosis and is part of the final common pathway to cirrhosis in chronic liver disease from all causes. The molecular mechanisms driving HSC differentiation are not fully understood. Because macroscopic tissue stiffening is a feature of fibrotic disease, we hypothesized that mechanical properties of the underlying matrix are a principal determinant of HSC activation. Primary rat HSC were cultured on inert polyacrylamide supports of variable but precisely defined shear modulus (stiffness) coated with different extracellular matrix proteins or poly-L-lysine. HSC differentiation was determined by cell morphology, immunofluorescence staining, and gene expression. HSC became progressively myofibroblastic as substrate stiffness increased on all coating matrices, including Matrigel. The degree rather than speed of HSC activation correlated with substrate stiffness, with cells cultured on supports of intermediate stiffness adopting stable intermediate phenotypes. Quiescent cells on soft supports were able to undergo myofibroblastic differentiation with exposure to stiff supports. Stiffness-dependent differentiation required adhesion to matrix proteins and the generation of mechanical tension. Transforming growth factor-β treatment enhanced differentiation on stiff supports, but was not required. HSC differentiate to myofibroblasts in vitro primarily as a function of the physical rather than the chemical properties of the substrate. HSC require a mechanically stiff substrate, with adhesion to matrix proteins and the generation of mechanical tension, to differentiate. These findings suggest that alterations in liver stiffness are a key factor driving the progression of fibrosis.
authors.affiliation: Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA.
authors.forename: Abby L
authors.initials: AL
authors.lastname: Olsen
authors.forename: Steven A
authors.initials: SA
authors.lastname: Bloomer
authors.forename: Erick P
authors.initials: EP
authors.lastname: Chan
authors.forename: Marianna D A
authors.initials: MD
authors.lastname: Gaça
authors.forename: Penelope C
authors.initials: PC
authors.lastname: Georges
authors.forename: Bridget
authors.initials: B
authors.lastname: Sackey
authors.forename: Masayuki
authors.initials: M
authors.lastname: Uemura
authors.forename: Paul A
authors.initials: PA
authors.lastname: Janmey
authors.forename: Rebecca G
authors.initials: RG
authors.lastname: Wells
mesh_terms: D000818:Animals; D002454:Cell Differentiation; D002478:Cells, Cultured; D003094:Collagen / Q000378:metabolism; D004338:Drug Combinations; D005109:Extracellular Matrix; D055166:Hepatic Stellate Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D007797:Laminin / Q000378:metabolism; D008103:Liver Cirrhosis / Q000378:metabolism / Q000473:pathology*; D008297:Male; D058628:Myofibroblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D011107:Polylysine / Q000378:metabolism; D011509:Proteoglycans / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D016212:Transforming Growth Factor beta / Q000494:pharmacology
chemical_list: D004338:Drug Combinations; D007797:Laminin; D011509:Proteoglycans; D016212:Transforming Growth Factor beta; C059485:matrigel; D011107:Polylysine; D003094:Collagen